Advertisement

The effect of clofibrate and pyridinol carbamate on the circulating immune complexes and cellular immune response in experimental atherosclerosis

  • Éva Szondy
    Affiliations
    Arteriosclerosis Research Group of the Ministry of Health, Somogyi Béla u. 33, 1085 Budapest, and HIM Department of Medicine of the Semmelweis Medical University, Eötvös L. u. 12, 1531 Budapest, Hungary
    Search for articles by this author
  • Maria Horvath
    Affiliations
    Arteriosclerosis Research Group of the Ministry of Health, Somogyi Béla u. 33, 1085 Budapest, and HIM Department of Medicine of the Semmelweis Medical University, Eötvös L. u. 12, 1531 Budapest, Hungary
    Search for articles by this author
  • G. Fost
    Affiliations
    Arteriosclerosis Research Group of the Ministry of Health, Somogyi Béla u. 33, 1085 Budapest, and HIM Department of Medicine of the Semmelweis Medical University, Eötvös L. u. 12, 1531 Budapest, Hungary
    Search for articles by this author
  • Erzsébet link
    Affiliations
    Arteriosclerosis Research Group of the Ministry of Health, Somogyi Béla u. 33, 1085 Budapest, and HIM Department of Medicine of the Semmelweis Medical University, Eötvös L. u. 12, 1531 Budapest, Hungary
    Search for articles by this author
  • J. Fehér
    Affiliations
    Arteriosclerosis Research Group of the Ministry of Health, Somogyi Béla u. 33, 1085 Budapest, and HIM Department of Medicine of the Semmelweis Medical University, Eötvös L. u. 12, 1531 Budapest, Hungary
    Search for articles by this author
  • S. Gerö
    Affiliations
    Arteriosclerosis Research Group of the Ministry of Health, Somogyi Béla u. 33, 1085 Budapest, and HIM Department of Medicine of the Semmelweis Medical University, Eötvös L. u. 12, 1531 Budapest, Hungary
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Cholesterui-fed rabbits were treated with clofibrate, pyridinol carbamate and with both drugs simultaneously. The quantity of circulating immune complexes in the sera of the animals was measured weekly and the migration inhibition test was carried out in the 12th week of the experiment. The trend of the changes in the concentration of the immune complexes was rather similar to that of the cellular immune response. Compared with the values obtained in the control animals, in the cholesterol-fed group a markedly higher level of immune complexes and a significant migration inhibition could be detected. The administration of clofibrate or pyridinol carbamate alone had no effect on the concentration of immune complexes. Pyridinol carbamate did not influence the migration inhibition; however, it became similar to the healthy controls in the clofibrate-treated group. Simultaneous treatment with both drugs resulted in a decrease in the quantity of immune complexes and a diminution of the migration inhibition.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Di Perri T.
        • Forconi S.
        • Auteri A.
        • Vittoria A.
        Action of cinnarizine on the hyperlipidaemia of experimental immune complex disease.
        Artery. 1977; 3: 233
        • Geertinger P.
        • Sørensen H.
        Complement and arteriosclerosis.
        Atherosclerosis. 1973; 18: 65
        • Füst G.
        • Székely J.
        • GerŐ S.
        Circulating immune complexes in vascular diseases.
        Lancet. 1977; 1: 193
        • Füst G.
        • Szondy E.
        • Székely J.
        • Gerő S.
        Studies on the occurrence of circulating immune complexes in vascular diseases.
        Atherosclerosis. 1978; 29: 181
        • Horváth M.
        • Alföldy P.
        • Ónody K.
        • Braun E.
        Immunological studies with aortic and venous tissue antigens, Part 3 (Examination of cell-mediated and humoral immune response induced by human vascular antigens).
        Paroi Artérielle/Arterial Wall. 1978; 4: 89
        • Gerő S.
        • Füst G.
        • Szondy E.
        • HorvAth M.
        • Székely J.
        • Link E.
        Circulating immune complexes in human and experimental vascular diseases.
        in: Proceedings of International Conference on Atherosclerosis, Milan Raven Press, New York, NY1978 (In press)
        • Johnson A.J.
        • Mowbray J.F.
        • Porter K.A.
        Detection of circulating immune complexes in pathological human sera.
        Lancet. 1975; 1: 762
        • Śvejcar J.
        • Johanovsky J.
        Demonstration of delayed (tuberculin) type hypersensitivity in vitro.
        Z. Immun.-Forsch. 1961; 122: 398
        • Robert L.
        • Robert M.
        • Moczar M.
        • Moczar E.
        Constituants macromoleculaires de la paroi arté-rielle — Antigénicité et role dans l'athérosclérose.
        in: Le ROle de la Paroi Artérielle dans l'Athérogénèse. C.N.R.S, Paris1968: 395
        • Rappaport F.
        • Eichhorn F.
        Sulfosalicylic acid as a substitute for paratoluene sulfonic acid. A. In the estimation of cholesterol.
        in: 3rd edition. Clin. Chim. Acta. 5. 1960: 161
        • Van Handel E.
        • Zilversmit D.B.
        Micromethod for the direct determination of serum triglycerides.
        J. Lab. Clin. Med. 1957; 50: 152
        • Report of a WHO scientific group
        The Role of Immune Complexes in Disease.
        WHO Technical Report Series, No. 606. 1977;
        • Minick C.R.
        • Murphy G.E.
        • Campbell W.G.
        Experimental induction of atherosclerosis by the synergy of allergic injury to arteries and lipid-rich diet.
        J. Exp. Med. 1966; 134: 635
        • Joffe V.T.
        • Zubzinskij Ju.N.
        • Nagornev V.A.
        • Klimov A.N.
        K immunologitsheskoy charakteristike experimentalnogo atherosclerosa.
        Bjull. Exp. Biol. Med. 1973; 75: 72
        • Shimamoto T.
        • Numano F.
        • Fujita T.
        • Ishioka T.
        • Atsumi T.
        Treatment of experimental and human atherosclerosis with pyridinol carbamate.
        Asian Med. J. 1965; 8: 5
        • Wu C.
        • Huang T.
        • Hsu C.
        Prevention of experimental atherosclerosis with pyridinol carbamate.
        Amer. Heart J. 1969; 77: 657
        • Shimamoto T.
        • Atsumi T.
        • Numano F.
        • Fujita T.
        Treatment of atherosclerosis with pyridinol carbamate.
        Progr. Biochem. Pharmacol. 1968; 4: 597
        • Kritchevsky D.
        • Tepper S.A.
        Influence of pyridinol carbamate on oxidation of cholesterol by rat liver mitochondria.
        Arzneimittel-Forsch. 1971; 21: 146
        • Kassira W.N.
        Pyridinol Carbamate as an Antiatherogenic Agent — Ultrastructural and Biochemical Study.
        Dissertation Abstr. Intern. B. 1976; 37: 2209